Merck & Co. has collaborated with Orna Therapeutics to develop and commercialize vaccines and therapeutics targeting oncology and infectious diseases. Merck (known as MSD outside of the US and Canada) will make an upfront payment of $150 million to circular RNA (oRNA) therapy firm Orna to discover, drive, and commercialize different programs. This payment will be expensed by Merck in the third quarter of this year. Orna has the potential to receive up to $3.5 billion in sales, development and…
Biomanufacturing services firm National Resilience will collaborate with Mayo’s Center for Regenerative Medicine in Minnesota. The collaboration will see Resilience and Mayo create process development labs, analytical development labs, and quality control labs at Mayo’s Center for Regenerative Medicine in Rochester, Minnesota, to jointly develop and progress cell therapies and other advanced modalities into the clinic. The partnership also hopes to attract third-party biotech companies interested in sponsoring clinical trials for new therapeutics, as well as collaborating on their process…